Nxera Pharma Co., Ltd. (TYO:4565)
926.00
-24.00 (-2.53%)
Jun 6, 2025, 3:30 PM JST
Nxera Pharma Employees
Nxera Pharma had 374 employees as of December 31, 2024. The number of employees increased by 24 or 6.86% compared to the previous year.
Employees
374
Change (1Y)
24
Growth (1Y)
6.86%
Revenue / Employee
79.76M JPY
Profits / Employee
-5.99M JPY
Market Cap
85.41B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Chugai Pharmaceutical | 5,026 |
Daiichi Sankyo Company | 18,726 |
Takeda Pharmaceutical Company | 49,281 |
HOYA Corporation | 35,702 |
Otsuka Holdings | 35,338 |
Astellas Pharma | 14,754 |
Olympus | 28,838 |
Shionogi & | 4,955 |
Nxera Pharma News
- 3 days ago - Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewsWire
- 4 days ago - Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases - GlobeNewsWire
- 8 days ago - Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewsWire
- 5 weeks ago - Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 - GlobeNewsWire
- 5 weeks ago - Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia - GlobeNewsWire
- 5 weeks ago - Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations - GlobeNewsWire
- 2 months ago - Nxera Pharma Announces Appointments to its Executive Leadership Team - GlobeNewsWire
- 2 months ago - Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder - GlobeNewsWire